Written questions by Dhesi.

Pursuant to the Answer of 3 March 2025 to Question 35028 on LGBT Veterans Independent Review, what progress he has made on recommendations (a) 31, (b) 35, (c) 36, (d) 38 and (e) 42.

For recommendation 31, NHS England, in partnership with the Royal College of General Practitioners (GPs), continues to encourage participation in the Veteran Friendly GP accreditation scheme. To date, over 99% of primary care networks have at least one accredited GP in their area. For recommendation 35, since June 2025, 100% of National Health Service trusts have been accredited as ‘veteran aware’. This achievement, led by the Veterans Covenant Healthcare Alliance, reflects a national commitment to providing compassionate, personalised care to the Armed Forces Community.As for recommendations 36 and 38, I refer the Hon. Member to the answers I gave on 31 October 2025 to Questions 84296 and 84297.Finally, for recommendation 42, we recognise the importance of training for NHS staff on the needs of the Armed Forces Community. The NHS National Armed Forces Training and Education Programme will see NHS staff across England receiving dedicated training to help them identify and support patients with military backgrounds. This will be provided through a variety of channels: face to face; webinars; train the trainer; and e-learning. This launched in October 2025 and is supported by £1.8 million of investment over three years.

What recent assessment he has made of the adequacy of the availability of lactose-free medication in the South East.

The patient’s doctor is best placed to understand their requirements and might consider it necessary to prescribe lactose free products, possibly by brand. Alternatively, the doctor might be able to stipulate “lactose free” on the prescription and liaise with local pharmacists to find a suitable product.The British National Formulary is an evidence-based independent drug formulary used by health professionals as a source of key information on the selection, prescribing, dispensing, and administration of medicines. It advises that the lactose content in most medicines is too small to cause problems in most lactose-intolerant patients. However, in patients with severe lactose intolerance, lactose content should be determined before prescribing, especially if they are taking several products containing lactose.It is a requirement to state the presence of lactose on the label of a medicine. All ingredients present in a medicine must be declared in the patient information leaflet (PIL). The PIL is provided in the packaging of all medicines. In addition, the Medicines and Healthcare products Regulatory Agency and the electronic medicines compendium can be used to see the composition of medicines licensed in the United Kingdom, with further information available at the following link:https://www.medicines.org.uk/emc

What estimate he has made of the number of patients admitted to hospital with (a) covid, (b) flu and (c) respiratory syncytial virus in (i) 2025, (ii) 2024 and (iii) 2023.

NHS England publishes data on hospital admissions, including due to influenza and respiratory syncytial virus (RSV). The data is available at the following link:https://digital.nhs.uk/data-and-information/publications/statistical/hospital-accident--emergency-activityNHS England publishes data on hospital admissions including those that relate to the number of patients admitted with COVID-19. The data is available at the following link:https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/The following table shows the number of hospital admissions for COVID-19, influenza, and RSV in 2023/24 and 2024/25:Hospital Admissions2023/242024/25Influenza28,00359,320RSV19,57219,457COVID-1935,50723,507Source: NHS England Digital

Whether he has made an assessment of the potential merits of introducing a screening programme to detect undiagnosed heart defects in young people.

In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and which supports implementation.The UK NSC last reviewed screening for sudden cardiac death (SCD) in people under the age of 39 years old in 2019 and concluded that population screening should not be offered. Further information is available at the following link:https://view-health-screening-recommendations.service.gov.uk/sudden-cardiac-death/The UK NSC is currently examining the evidence for SCD screening and will open a public consultation to seek comments from members of the public and stakeholders on this in due course.

If he will ask the National Institute for Health and Care Excellence to respond to the coroner's Prevention of Future Death report following the death of Chloe Burgess.

The National Institute for Health and Care Excellence responded to the Hampshire Coroner’s Prevention of Future Death Report following the death of Chloe Burgess on 28 April 2025. The report is available at the following link:https://www.judiciary.uk/prevention-of-future-death-reports/chloe-burgess-prevention-of-future-deaths-report/

What progress he has made on implementing recommendation 38 of the LGBT Veterans Independent Review, published in May 2023.

Recommendation 36 relates to the expansion of the Veterans’ Covenant Healthcare Alliance (VCHA) accreditation scheme to include care homes and hospices. In July 2024, a pilot was launched by the Royal Star and Garter, supported by the VCHA. An evaluation of the pilot, led by the Royal British Legion, commenced in summer 2025. The evaluation findings will assess the practical viability of the scheme and will be accompanied by a full analysis of the options and associated financial costs.Recommendation 38 relates to treatment for addiction. Veterans can access all substance misuse services available to non-veterans. In addition, the National Health Service has commissioned Op COURAGE, the veterans’ mental health and wellbeing service which provides support to veterans with substance misuse and mental health issues. NHS England are developing plans to provide training and education about the needs of the Armed Forces community to NHS staff through the National Armed Forces training and education programme. This will include NHS services that provide support to veterans with addiction issues.

What progress he has made on implementing recommendation 36 of the LGBT Veterans Independent Review, published in May 2023.

Recommendation 36 relates to the expansion of the Veterans’ Covenant Healthcare Alliance (VCHA) accreditation scheme to include care homes and hospices. In July 2024, a pilot was launched by the Royal Star and Garter, supported by the VCHA. An evaluation of the pilot, led by the Royal British Legion, commenced in summer 2025. The evaluation findings will assess the practical viability of the scheme and will be accompanied by a full analysis of the options and associated financial costs.Recommendation 38 relates to treatment for addiction. Veterans can access all substance misuse services available to non-veterans. In addition, the National Health Service has commissioned Op COURAGE, the veterans’ mental health and wellbeing service which provides support to veterans with substance misuse and mental health issues. NHS England are developing plans to provide training and education about the needs of the Armed Forces community to NHS staff through the National Armed Forces training and education programme. This will include NHS services that provide support to veterans with addiction issues.

Whether he plans to include diagnosis targets for myeloma in the national cancer plan for England.

Early diagnosis is a key focus of the National Cancer Plan. It is a priority for the Government to support the National Health Service to diagnose cancer, including blood cancers such as myeloma, as early and quickly as possible, and to treat it faster, to improve outcomes.To tackle late diagnoses of blood cancers, the NHS is implementing non-specific symptom pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways.We will get the NHS diagnosing blood cancers earlier and treating them faster, and we will support the NHS to increase capacity to meet the demand for diagnostic services through investment, including for magnetic resonance imaging and computed tomography scanners.The National Cancer Plan will include further details on how we will improve outcomes for cancer patients, including speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates. Having consulted with key stakeholders and patient groups, the Plan will be published early in the new year.

What recent steps he has taken to help reduce the time taken to diagnose myeloma.

Information on the average time taken to diagnose myeloma in the South East is not held centrally. We publish 28-Day Faster Diagnosis data by suspected cancer, including provider and commissioner data, monthly. The latest publication is available at the following link:https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/monthly-data-and-summaries/2025-26-monthly-cancer-waiting-times-statistics/cancer-waiting-times-for-august-2025-26-provisional/We recognise that there is more to be done to ensure that patients have timely access to diagnosis, and we remain committed to diagnosing all cancer types earlier, including myeloma. To tackle late diagnoses, the National Health Service is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.

What recent estimate he has made of the average time taken to diagnose myeloma in the South East.

Information on the average time taken to diagnose myeloma in the South East is not held centrally. We publish 28-Day Faster Diagnosis data by suspected cancer, including provider and commissioner data, monthly. The latest publication is available at the following link:https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/monthly-data-and-summaries/2025-26-monthly-cancer-waiting-times-statistics/cancer-waiting-times-for-august-2025-26-provisional/We recognise that there is more to be done to ensure that patients have timely access to diagnosis, and we remain committed to diagnosing all cancer types earlier, including myeloma. To tackle late diagnoses, the National Health Service is implementing non-specific symptom (NSS) pathways for patients who present with symptoms such as weight loss and fatigue, which do not clearly align to a tumour type. Blood cancers are one of the most common cancer types diagnosed through these pathways. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.

What steps he is taking to reduce group B strep infections in newborn babies.

The United Kingdom uses the Royal College of Obstetricians and Gynaecologists’ risk-based approach whereby those women identified as being at increased risk of having a baby affected by Group B streptococcus (GBS) are managed according to agreed clinical guidelines on the prevention of early on-set neonatal GBS infection.To improve understanding, prevention, and treatment of GBS infection, the Department is supporting a trial, funded by the National Institute for Health and Care Research. It aims to determine whether routine testing for GBS for all women, either in late pregnancy or on admission for labour with point of care testing, reduces early-onset neonatal sepsis compared to the current approach of risk-based screening.The UK National Screening Committee (NSC) will review its recommendation considering the evidence from the trial, after the report is presented.The UK NSC previously reviewed the evidence to screen for GBS at 35 to 37 weeks of pregnancy in 2017 and concluded that there was insufficient evidence to demonstrate that the benefits of screening would outweigh the harms. This was because the test currently available cannot accurately distinguish between those mothers whose babies are at risk and those who are not. This means that many women would unnecessarily be offered antibiotics during labour, with the balance of harms and benefits from this approach being unknown.

What steps his Department is taking to ensure the consistent implementation of (a) Non-Specific Symptom pathways, (b) GP direct access and (c) NHS England Best Practice Timed Pathways to ensure (i) faster and (ii) earlier diagnosis of people with pancreatic cancer.

NHS England has completed the national roll-out of non-specific symptom (NSS) pathways to support faster diagnosis of cancer in patients who present with symptoms that do not align with a single cancer site.We are investing an additional £1.1 billion in general practices (GPs), bringing total GP Contract spend to £13.4 billion in 2025/26, the biggest increase in over a decade. NHS England has also expanded GP direct access to diagnostic tests, enabling faster investigation of concerning symptoms.The National Health Service has also launched a new £2 million programme which is funding 300 GPs to identify pancreatic cancer early by screening high-risk patients over 60 years old with new diabetes diagnoses and unexplained weight loss for urgent testing.NHS England continues to implement Best Practice Timed Pathways to ensure consistent and faster diagnosis in line with the Faster Diagnosis Standard. Alongside this, it is working with Pancreatic Cancer UK on a Family History Checker to help individuals assess inherited risk, and has launched the National Inherited Cancer Predisposition Register, which supports earlier identification and screening of high-risk individuals.

What assessment his Department has made of the potential merits of a national multi-cancer case finding programme to identify individuals at high risk of (a) pancreatic cancer and (b) all other cancers.

NHS England is developing case-finding approaches for less survivable cancers where the evidence supports this, including pancreatic cancer.This work includes the development of a public-facing Family History Checker in partnership with Pancreatic Cancer UK, which enables individuals and families affected by pancreatic cancer to assess inherited risk. Those identified as being at risk are referred directly to the European Registry of Hereditary Pancreatic Diseases research trial. Referrals can be made by any healthcare professional or by individuals via self-referral, contributing to a more consistent and centralised approach to case-finding.The National Disease Registration Service has launched the National Inherited Cancer Predisposition Register, which identifies individuals at increased inherited risk of a wide range of cancers, including pancreatic cancer. The register supports targeted screening and surveillance and will act as an electronic referral route into national screening programmes where these exist.

What steps his Department is taking to support the (a) development and (b) rollout of biomarker tests to support early detection of (i) pancreatic cancer and (ii) other less survivable cancers in primary care services.

million NHS programme. This is funding more than 300 general practices (GPs) to identify pancreatic cancer early by screening high-risk patients over 60 years old with new diabetes diagnoses and unexplained weight loss. More than 80 GPs across England have begun using the initiative. It will be extended to the other general practices participating in the trial by the end of the year.The National Disease Registration Service (NDRS) is developing a National Inherited Cancer Predisposition Register (NICPR), which launched on 30 June. The NICPR looks at a wide range of cancers for which there is an increased inherited risk, including for less survivable cancers. It aims to identify high-risk individuals who are eligible for targeted screening and surveillance, and will act as an electronic referral route into national screening programmes where these exist.

How much his Department has spent on (a) providing maternity care and (b) settling legal cases of medical negligence related to maternity care in each of the last four years.

In regard to maternity care spend, according to the Patient-Level Costing dataset from the National Cost Collection for the National Health Service, the annual spend for providing maternity care was as follows:£4,855,676,069.19 for 2021/22;£4,722,376,594.65 for 2022/23; and£5,174,161,637.32 for 2023/24.Data is not yet available for the 2024/25 financial year.NHS Resolution manages clinical negligence and other claims against the NHS in England. The table attached shows the spend on maternity clinical claims either closed or settled with a periodical payment order (PPO) between the 2021/22 and 2024/25 financial years, broken down by closure, or settlement PPO, year, for claims with obstetrics or neonatology as the primary specialty.The data includes the damages and legal costs paid up until 31 March 2025. It does not include future periodical payments on settled claims that are due after the end of the 2024/25 financial year.Please note that this is different to the value of claims “notified” in a year for obstetrics and neonatology. Data on “notified claims value” only includes an early estimate of the eventual settlement value if all the claims were to settle with damages.

What assessment he has made of the potential merits of introducing self-sampling for cervical screening as an alternative to clinic-based cervical screening.

Following the announcement to introduce human papilloma virus (HPV) self-sampling in the National Health Service cervical screening programme for the under-screened population, the NHS has begun planning an in-service evaluation (ISE) of HPV self-sampling in the wider population.The purpose of the ISE is to ensure the self-sampling test is as accurate at detecting HPV compared with a clinician-collected specimen, and to evaluate its impact on cervical screening uptake. The findings of the ISE will inform any future recommendation from the UK National Screening Committee to Ministers to offer self-sampling across the whole population.

What recent steps his Department is taking to reduce treatment waiting times for people with prostate cancer in the South East.

The Government understands that more needs to be done to improve outcomes for all patients with prostate cancer, including in the South East.NHS England has introduced a best-practice timed pathway for prostate cancer so that those suspected of prostate cancer receive a multi-parametric magnetic resonance imaging scan first, which ensures that only those men most at risk of having cancer undergo an invasive biopsy. The AI in Health and Care Award has also been established, which aims to accelerate the testing and development of artificial intelligence (AI) technologies. £113 million has already been allocated to support 86 AI technologies, and three of these projects specifically relate to prostate cancer, one of which is the Paige prostate cancer detection tool, developed by the University of Oxford.The Department will publish a National Cancer Plan which will include further details on how we will improve outcomes for cancer patients across England, including the South East, speed up diagnosis and treatment, and ensure that patients have access to the latest treatments and technology.

If he will make an assessment of the potential merits of introducing a national prostate cancer screening programme.

The UK National Screening Committee (UK NSC), which advises ministers on all screening matters, commissioned an evidence review modelling the clinical effectiveness and cost of several approaches to prostate cancer screening. This included different potential ways of screening the whole population and targeted screening aimed at groups of people identified as being at higher-than-average risk, such as black men or men with a family history of cancer.The modelling and evidence review are now complete, and the reports are being considered by the UK NSC and experts. Subject to no further revisions being required, the UK NSC plans to start a three-month public consultation towards the end of 2025. After this, the UK NSC will make a recommendation about screening for prostate cancer. Ministers will then be asked to consider whether to accept the recommendation.

What recent assessment his Department has made of the adequacy of the supply of epilepsy medications.

The Department is working hard with industry to help resolve intermittent supply issues with some epilepsy medications. As a result of ongoing activity and intensive work, including asking manufacturers to expedite deliveries, most issues have been resolved.We are currently aware of a supply issue affecting topiramate 25mg, 50mg, 100mg and 200mg tablets and phenobarbital 15mg tablets, used in the management of epilepsy, from certain manufacturers. Resupply from the affected manufacturers is yet to be confirmed but stock remains available from alternative manufacturers to meet patient demand, and we have issued management guidance to the National Health Service.

What recent steps he has taken to help reduce the average diagnosis time for endometriosis.

It is unacceptable that women can wait too long for an endometriosis diagnosis and this government is committed to improving the diagnosis, treatment and ongoing care for gynaecological conditions including endometriosis.Tackling waiting lists is a key part of our Health Mission. We have now exceeded our pledge to deliver an extra two million operations, scans, and appointments, having now delivered 4.9 million more appointments.In November 2024, the National Institute for Health and Care Excellence updated its guideline on the diagnosis and management of endometriosis to make firmer recommendations on referral and investigations, which will help women receive a diagnosis and effective treatment faster. This includes updated recommendations that for women with symptoms of endometriosis, initial pharmacological treatment should take place in primary care, and that this can take place in parallel with additional investigations and referral to secondary care if needed. The guideline is available at the following link:https://www.nice.org.uk/guidance/ng73